Replies to post #480962 on Anavex Life Sciences Corp (AVXL)

[bb8675309]

Blarcamesine has basically been proven to benefit and be good for the people. That proof has now been stamped by 58 of the best experts. Up until now that hasn't been so. These few naysayers here 24/7 are here to twist and distort reports and to create fear uncertainty and doubt. MABS have been proven to kill people while blarcamesine has proven through nine years of drug trial results, that it is the best drug to treat Alzheimer disease and should be the new SOC drug. Peer review results is the stamp of approval by the experts. Period!

[mike_dotcom]

But how could those 58 experts possibly know more than Doc?

[Investor2014]

Let me try to be as constructive as I can and much prefer to be.

The purpose and role of a peer-reviewed paper, and the contributions of the 58 trial investigators and authors listed within it, are often misinterpreted. Simply listing the names of the contributors does not automatically guarantee that the findings are indisputable or universally accepted.

Key Points About the Paper:

Quality of the Paper:
It is a well-constructed and promising paper that is internally consistent (within the limits of what has been disclosed) and free from obvious errors as noted by the journal’s peer reviewers. However, peer reviewers only provide an initial quality check and are not final arbiters of the claim’s universal validity.

Role of the 58 Authors:
The listing of 58 experts does not imply infallibility. Their inclusion indicates that they contributed to specific parts of the study, such as data acquisition, analysis, interpretation, and manuscript review.

Not all the listed authors were involved equally. A smaller group likely conducted the key analyses and drafted the core of the paper.

Regulatory Approval:
Regulatory bodies like the EMA and FDA do not base decisions solely on the authorship or reputation of those listed. Instead, they rigorously review the full underlying dataset—something far more detailed than what is included in a peer-reviewed publication. The approval process involves independent verification of the claims made, ensuring they are robust and reproducible.

Limitations of the Paper:
The paper itself acknowledges certain key limitations. It does not contain all the granular details regulators or investors might require for a full evaluation. As a result, investors and interested parties should maintain a degree of skepticism until the broader data is made available and analysed. We will hopefully find that the Anavex MAA will pass the EMA clock stop one, which would be a strong indication that the data and conclusion do indeed point towards EMA approval.

On Constructive Discussion:
Rather than dismissing concerns as unfounded (FUD—fear, uncertainty, doubt), it can be more productive to ask thoughtful questions. Phrases like:

- “I’m not sure I understand your conclusions. Could you clarify or provide further references?”
- “What do you think about this specific aspect of the paper?
- "I don't much experience with statistics, but I would like to better understand point. Could explain layman terms how to understand it?

This approach fosters a more collaborative and insightful discourse where different perspectives can coexist constructively. Disagreements are natural and valuable in fields like biotech investment and scientific inquiry, as they provide opportunities for growth, learning, and informed decision-making.

In summary, the presence of expert authors on a paper enhances its credibility but does not make it immune to scrutiny. Engaging with the reasoning behind skepticism instead of dismissing it outright helps cultivate a more informed and respectful discussion.